Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cellerant Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Cellerant is a clinical-stage biotechnology company developing a portfolio of adult stem cell-derived products that could potentially regulate the hematopoietic (blood forming) system. It currently has two products in clinical development: a highly purified hematopoietic stem cell product that is a curative therapy for sickle cell disease, autoimmune diseases and cancers, and a manufactured cell product for the treatment of neutropenia in patients at risk for infection following stem cell transplant or chemotherapy.

You may also be interested in...



Stem Cells: What's the Business Model?

The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.

Stem Cells: What's the Business Model?

The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.

Cancer Stem Cells: A New Approach to Treating Cancer

Cancer stem cells are a hot, promising new approach to treating cancer--one which may not only prevent cancer from spreading, but also help diagnose and even cure the disease. Start-ups are beginning to emerge, and so is investor interest.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel